

**Translation**

Notice: This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Alfresa Holdings Corporation  
March 13, 2025

**Notice Regarding Achievement of ISO 9001 Certification by Alfresa Corporation:  
Efforts to Improve Logistics Quality in the Alfresa Group**

Alfresa Corporation (head office: Chiyoda-ku, Tokyo; Representative Director & President: Yusuke Fukujin; hereinafter “Alfresa”), a subsidiary of Alfresa Holdings Corporation that is active in the Ethical Pharmaceuticals Wholesaling Business, has achieved certification for ISO 9001, a global standard for quality management systems, at the Logistics Operations Department of its Logistics Division and three Distribution Centers. Details are as follows.

The Alfresa Group’s Principles<sup>\*1</sup> state that “we always provide reliable products and services and strive to enhance customer satisfaction.” In addition, under its policy to “build an optimal logistics network in keeping with PIC/S GDP standards,” which is set forth in the business policies of the Ethical Pharmaceuticals Wholesaling Business in the 22–24 Mid-term Management Plan: Leap into the Future “An Evolving Healthcare Consortium,”<sup>\*2</sup> the Group works to build a system that enables it to deliver every product safely, securely, and in high quality. As part of efforts to improve logistics quality, the Alfresa Group promotes the achievement of ISO 9001 certification throughout the Group. Thanks to these efforts, the Group has achieved certification at the Logistics Operations Department of its Logistics Division, Saitama Distribution Center, Aichi Distribution Center, and Osaka Distribution Center.

The Group is committed to enhancing satisfaction among customers and business partners by continuing Groupwide efforts to achieve ISO certification.

\*1 The Alfresa Group’s Principles

<https://www.alfresa.com/eng/about/philosophy/>

\*2 Announcement of the Formulation of the 22–24 Mid-term Management Plan: Leap into the Future “An Evolving Healthcare Consortium” (published on May 16, 2022, on the Alfresa Holdings Corporation corporate website)

[https://ssl4.eir-parts.net/doc/2784/ir\\_material17/183216/00.pdf](https://ssl4.eir-parts.net/doc/2784/ir_material17/183216/00.pdf)

## ■Certification Details

Certified business sites	Alfresa, Logistics Division, Logistics Operations Department Alfresa, Logistics Division, Logistics Operations Department, Saitama Distribution Center Alfresa, Logistics Division, Logistics Operations Department, Aichi Distribution Center Alfresa, Logistics Division, Logistics Operations Department, Osaka Distribution Center
Validity period	February 12, 2025, to February 12, 2028 First certified on February 12, 2025
Scope of certification	Logistics services for the order, receipt, shipment, and storage of ethical pharmaceuticals, medical devices, medical diagnostic reagents, nursing care products, health foods, regenerative medicines, and over-the-counter pharmaceuticals, and management of warehouse operations subcontracting for receipt, shipment, and storage thereof
Authorizing institution	United Kingdom Accreditation Service (UKAS)*3
Certifying institution	SGS Japan Inc.*4

\*3 National accreditation body for the United Kingdom

\*4 Leading company for private inspection, verification, testing, and certification services, established in 1987. Supports a wide range of industrial fields in Japan and overseas, while the SGS Group as a whole offers services globally through its more than 2,500 laboratories and business facilities and approximately 99,500 employees in over 115 countries.

### About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥2.8 trillion for the fiscal year ended March 31, 2024. For more information, please see: <https://www.alfresa.com/eng/>